Use of fluoroquinolones as prophylactic agents in patients with neutropenia

Pediatric Infectious Disease Journal

Volumn 16, Issue 1, 1997, Pages 135-139

  Patrick, Christian C ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

bacterial infections; Fluoroquinolones; neutropenia; selective decontamination

Indexed keywords

CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; NORFLOXACIN; OFLOXACIN; POLYMYXIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIUM ADHERENCE; CHILD; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; HUMAN TISSUE; INFECTION PREVENTION; INFECTION RISK; INTESTINE FLORA; MAJOR CLINICAL STUDY; META ANALYSIS; NEUTROPENIA; PRIORITY JOURNAL;

ANTI-INFECTIVE AGENTS; ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTIONS; CIPROFLOXACIN; DIGESTIVE SYSTEM; GASTROINTESTINAL DISEASES; HUMANS; IMMUNOCOMPROMISED HOST; NEUTROPENIA;

EID: 0031041208     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199701000-00038     Document Type: Conference Paper

References (39)

1. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-40.
2. Schimpff SC, Young VM, Greene WH, Vermeulen GD, Moody MR, Wiernik PH. Origin of infection in acute nonlymphocytic leukemia: significance of hospital acquisition of potential pathogens. Ann Intern Med 1972;77:707-14.
3. Yates JW, Holland JF. A controlled study of isolation and endogenous microbial suppression in acute myelocytic leukemia patients. Cancer 1973;32:1490-8.
4. Schimpff SC, Greene WH, Young VM, et al. Infection prevention in acute nonlymphocytic leukemia: laminar air flow room reverse isolation with oral, nonabsorbable antibiotic prophylaxis. Ann Intern Med 1975;82:351-8.
5. Vollaard EJ, Clasener HAL. Colonization resistance. Antimicrob Agents Chemother 1994;38:409-14.
6. Moore WEC, Holdeman LV. Human fecal flora: the normal flora of 20 Japanese Hawaiians. Appl Microbiol 1974;27:961-79.
7. Vollaard EJ, Clasener HAL, Janssen AJHM. The contribution of Escherichia coli to microbial colonization resistance. J Antimicrob Chemother 1990;26:411-18.
8. Meyer-Severs GJ, Van Santen E. Variations in anaerobic fecal flora of ten healthy human volunteers with special reference to the Bacteroides fragilis and Clostridium difficile. Zentralbl Bakteriol Hyg A 1986;261:43-52.
9. Van der Waaij D. The immunoregulation of the intestinal flora; consequences of decreased thymus activity and broad-spectrum antibiotic treatment. Zentralbl Bakteriol Suppl 1965;13:73-89.
10. Savage DC. Introduction to mechanisms of association on indigenous microbes. Am J Clin Nutr 1979;32:113-8.
11. Van der Waaij D, Tieleman-Speltie TM, De Roeck Houben AMJ. Relation between the faecal concentrations of various potentially pathogenic microorganisms and infections in individuals (mice) with severely decreased resistance to infection. Antonie van Leeuwenhoek 1978;44:395-405.
12. Clasener HAL, Vollaard EJ, van Saene HKF. Long-term prophylaxis of infection by selective decontamination in leukopenia and in mechanical ventilation. Rev Infect Dis 1987; 9:295-328.
13. Van der Waaij D. Selective decontamination of the digestive tract: general principles. Eur J Cancer Clin Oncol 1988; 24(Suppl 1):S1-4.
14. Hughes WT, Kuhn S, Chaudhary SC, et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1977;297:1419-26.
15. Gurwith MJ, Brunton JL, Lank BA, Harding GR, Ronald AR. A prospective controlled investigation of prophylactic trimethoprim-sulfamethoxazole in hospitalized granulocytopenic patients. Am J Med 1979;66:248-56.
16. Kauffman CA, Liepman MK, Bergman AG, Mioduszewski J. Trimethoprim/sulfamethoxazole prophylaxis in neutropenic patients: reduction of infections and effect on bacterial and fungal flora. Am J Med 1983;74:599-607.
17. Wilson JM, Guiney DG. Failure of oral trimethoprim/ sulfamethoxazole prophylaxis in acute leukemia: isolation of resistant plasmids from strains of Enterobacteriaceae causing bacteremia. N Engl J Med 1982;306:16-20.
18. Pizzo PA, Robichaud KJ, Edwards BK, Schumaker C, Kramer BS, Johnson A. Oral antibiotic prophylaxis in patients with cancer: a double blind randomized placebo controlled trial. J Pediatr 1983;102:125-33.
19. Wade JC, de Jongh CA, Newman KA, Crowley J, Wiernik PH, Schimpff SC. Selective antimicrobial modulation as prophylaxis against infection during granulocytopenia: trimethoprim-sulfamethoxazole vs nalidixic acid. J Infect Dis 1983;147:624-34.
20. Crump B, Wise R, Dent J. Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicrob Agents Chemother 1983;24:784-6.
21. Hooper DC, Wolfson JS. Fluoroquinolone antimicrobial agents. N Engl J Med 1991;324:384-94.
22. Rozenberg-Arska M, Dekker AW, Verhoef JA. Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: the effect of fecal flora. J Infect Dis 1985;152: 104-7.
23. Winston DJ, Ho WG, Nakao SL, Gale RP, Champlin RE. Norfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. Am J Med 1986;80: 884-90.
24. Dekker AW, Rozenberg-Arska M, Verhoef J. Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Ann Intern Med 1987;106:7-12.
25. Karp JE, Merz WG, Hendricksen C, et al. Oral norfloxacin for prevention of Gram negative bacterial infections in patients with acute leukemia and granulocytopenia: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1987; 106:1-7.
26. Bow EJ, Rayner E, Louie TJ. Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia: the trade-off for reduced Gram-negative sepsis. Am J Med 1988; 84:847-54.
27. Cruciani M, Concia E, Navarra A, et al. Prophylactic co-trimoxazole versus norfloxacin in neutropenic children: perspective randomized study. Infection 1989;17:65-9.
28. Liang RH, Yung RW, Chan TK, et al. Ofloxacin versus co-trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy. Antimicrob Agents Chemother 1990;34:215-8.
29. Winston DJ, Ho WG, Bruckner DA, Gale RP, Champlin RE. Ofloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. Am J Med 1990;88: 36-42.
30. The GIMEMA Infection Program. Prevention of bacterial infection in neutropenic patients with hematologic malignancies: a randomized, multicenter trial comparing norfloxacin with ciprofloxacin. Ann Intern Med 1991;115:7-12.
31. Lew MA, Kehoe K, Ritz J, et al. Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. Transplantation 1991;51:630-6.
32. Patrick CC, Adair JR, Warner WC Jr, et al. Safety of ciprofloxacin as a prophylactic agent for prevention of bacterial infections in pediatric bone marrow transplant (BMT) patients [Abstract LM 17]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995:329.
33. Bochud PY, Eggiman PH, Calandra TH, Van Melle G, Saghafi L, Francioli P. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis 1994;18:25-31.
34. Dekker AW, Rozenberg-Arska M, Verdonck LF. Prevention of bacteremia causes by hemolytic streptococci by roxithromycin in patients treated with intensive cytoxic treatment. Hematol Bluttransfus 1990;33:551-4.
35. Wolfson JS. Quinolone antimicrobial agents: adverse effects and bacterial resistance. Eur J Clin Microbiol Infect Dis 1989;8:1080-92.
36. Chysky V, Kapila K, Hullmann R, Arcieri G, Schact P, Echols R. Safety of ciprofloxacin in children: worldwide clinical experience based on compassionate use - emphasis on joint evaluation. Infection 1991;19:3-10.
37. Patrick CC. Data on file, Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN.
38. Stein GE. Drug interactions with fluoroquinolones. Am J Med 1991;91(Suppl 6A):81S-86S.
39. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 1992;14:1201-7.